Qiagen stock gains institutional backing as BlackRock stake disclosed
Published on 09/19/2026 at 11:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Qiagen N.V. stock (ISIN NL0012169213) is trading close to its Wall Street consensus price target as of September 18, 2026, while a new regulatory filing shows BlackRock holding 11.58 percent of the company’s capital and 12.99 percent of voting rights as of September 14, 2026.
BlackRock’s stake underlines institutional interest
According to Deutsche Boerse, the Netherlands Authority for the Financial Markets notified Qiagen on September 18, 2026 that BlackRock, Inc. reported an 11.58 percent capital interest and 12.99 percent voting rights in Qiagen based on a transaction dated September 14, 2026.
The voting rights notice shows that BlackRock’s 11.58 percent capital interest is composed of 8.69 percent indirectly real holdings and 2.89 percent indirectly potential holdings, while the 12.99 percent voting rights position includes 9.90 percent indirectly real voting rights and 3.09 percent indirectly potential voting rights, highlighting a significant institutional presence in Qiagen’s shareholder base.TradingView
Analysts see limited upside at current price
Qiagen stock is covered broadly by equity analysts, and the shares currently carry a consensus Hold rating.MarketBeat According to the same overview as of September 18, 2026, Qiagen’s consensus price target stands at USD 43.51, very close to its recent trading level of USD 43.84, implying only a small downside of about 0.8 percent from that snapshot price.
The MarketBeat data indicate an average rating score of 2.43 on a scale where 1 represents Strong Buy and 5 represents Sell, based on 1 strong buy rating, 4 buy ratings and 9 hold ratings for Qiagen, with no sell recommendations recorded in the past 90 days.MarketBeat For investors, this mix of largely neutral to positive opinions and a price already near the consensus target suggests that the newly disclosed BlackRock stake, rather than a major valuation gap, is the current key driver of the story.
CEO transition and extraordinary meeting add governance angle
Alongside the changing shareholder structure, Qiagen is undergoing a leadership transition that will be formalized at an upcoming shareholder vote. As Qiagen announced in a press release dated September 18, 2026, the company has called an Extraordinary General Meeting of Shareholders for November 6, 2026, at 2:00 p.m. CET to vote on appointing Jonathan M. Pratt to the Managing Board.
According to the same company statement, Pratt joined Qiagen as Chief Executive Officer on September 1, 2026 and, subject to shareholder approval, will sit on the two-member Managing Board alongside long-standing Chief Financial Officer Roland Sackers, while shareholders will also vote on the discharge of former CEO Thierry Bernard for his service through September 1, 2026.Yahoo Finance The combination of a fresh CEO and a major institutional holder can sharpen the governance focus around Qiagen for shareholders ahead of the November meeting.
Stock trades near recent levels
Per recent data compiled by MarketBeat, Qiagen stock traded at around USD 43.84 on the New York Stock Exchange on September 18, 2026, down 1.23 percent on the day, and remained close to the consensus price target of USD 43.51 mentioned above.MarketBeat This places the stock in a zone where the market appears to have priced in a good part of the current fundamentals and corporate developments, including the CEO change and the BlackRock disclosure.
Qiagen stock - key data
- Company: Qiagen N.V.
- ISIN: NL0012169213
- Ticker: QGEN
- Trading venue: New York Stock Exchange
- Sector / Industry: Health care / Biotechnology tools
- Index membership: S&P 500
